Halozyme Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HALO Nasdaq 2836 halozyme.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Halozyme Therapeutics, Inc.

Are Medical Stocks Lagging Ardelyx (ARDX) This Year? - Jan 12th, 2026 7:40 am
1 Surging Stock Worth Investigating and 2 We Brush Off - Jan 11th, 2026 9:39 pm
How Halozyme’s ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Jan 10th, 2026 4:09 am
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains - Jan 10th, 2026 1:13 am
HALO or AXSM: Which Is the Better Value Stock Right Now? - Jan 9th, 2026 9:40 am
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® - Jan 8th, 2026 6:00 am
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? - Jan 7th, 2026 9:04 pm
Smorgasbord Of Buy Points Kicks Off 2026. Google, Nvidia On The Menu. - Jan 7th, 2026 9:25 am
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Jan 7th, 2026 6:12 am
CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls - Jan 6th, 2026 7:38 am
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - Jan 5th, 2026 5:00 am
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - Jan 1st, 2026 1:30 pm
Here’s What Analysts Think About Halozyme Therapeutics (HALO) - Dec 31st, 2025 9:41 am
Halozyme Therapeutics Stock Sees Relative Strength Rating - Dec 23rd, 2025 10:42 am
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory - Dec 23rd, 2025 3:10 am
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed - Dec 23rd, 2025 1:10 am
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? - Dec 22nd, 2025 10:07 pm
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’ - Dec 22nd, 2025 7:00 am
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - Dec 18th, 2025 5:00 am
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics - Dec 17th, 2025 6:30 am